medwireNews: The US FDA has given approval for the use of the antibody–drug conjugate brentuximab vedotin in patients undergoing chemotherapy for treatment-naïve stage III or IV classical Hodgkin lymphoma.
The decision follows positive findings from the ECHELON-1 trial comparing outcomes for patients given a regimen of doxorubicin, vinblastine and dacarbazine alongside bleomycin or brentuximab vedotin.
The recommended intravenous infusion of brentuximab vedotin is 1.2 mg/kg up to a maximum of 120 mg every 2 weeks for 12 doses, with primary granulocyte colony-stimulating factor prophylaxis recommended alongside chemotherapy.
Common reactions with the agent include neutropenia, anemia, peripheral sensory neuropathy, gastrointestinal side effects, and pyrexia. In addition, the treatment has a boxed warning on the risk of John Cunningham virus infection leading to progressive multifocal leukoencephalopathy.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group
See also: